These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32445926)

  • 21. Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.
    Busch AB; Greenfield SF; Reif S; Normand ST; Huskamp HA
    J Subst Abuse Treat; 2020 Aug; 115():108040. PubMed ID: 32600627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residential and outpatient treatment completion for substance use disorders in the U.S.: Moderation analysis by demographics and drug of choice.
    Stahler GJ; Mennis J; DuCette JP
    Addict Behav; 2016 Jul; 58():129-35. PubMed ID: 26925821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting.
    Morgan JR; Barocas JA; Murphy SM; Epstein RL; Stein MD; Schackman BR; Walley AY; Linas BP
    JAMA Netw Open; 2020 Dec; 3(12):e2029676. PubMed ID: 33320266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
    Nguyen T; Andraka-Christou B; Simon K; Bradford WD
    J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
    Marsden J; Tai B; Ali R; Hu L; Rush AJ; Volkow N
    Addiction; 2019 Aug; 114(8):1346-1353. PubMed ID: 30614096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder.
    Alinsky RH; Hadland SE; Matson PA; Cerda M; Saloner B
    J Adolesc Health; 2020 Oct; 67(4):542-549. PubMed ID: 32336560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
    Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
    J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis.
    Kimmel SD; Walley AY; Li Y; Linas BP; Lodi S; Bernson D; Weiss RD; Samet JH; Larochelle MR
    JAMA Netw Open; 2020 Oct; 3(10):e2016228. PubMed ID: 33052402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projected Estimates of Opioid Mortality After Community-Level Interventions.
    Linas BP; Savinkina A; Madushani RWMA; Wang J; Eftekhari Yazdi G; Chatterjee A; Walley AY; Morgan JR; Epstein RL; Assoumou SA; Murphy SM; Schackman BR; Chrysanthopoulou SA; White LF; Barocas JA
    JAMA Netw Open; 2021 Feb; 4(2):e2037259. PubMed ID: 33587136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
    Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
    Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medications For Opioid Use Disorder Increased Among Louisiana Medicaid Enrollees During Policy Reforms, 2018-21.
    Sugarman OK; Li W; Saloner B
    Health Aff (Millwood); 2024 Jan; 43(1):46-54. PubMed ID: 38190602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States.
    Gaeta Gazzola M; Carmichael ID; Christian NJ; Zheng X; Madden LM; Barry DT
    Subst Abus; 2023; 44(1):62-72. PubMed ID: 37226909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study.
    David AR; Sian CR; Gebel CM; Linas BP; Samet JH; Sprague Martinez LS; Muroff J; Bernstein JA; Assoumou SA
    J Subst Abuse Treat; 2022 Nov; 142():108870. PubMed ID: 36084559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013-2017.
    Nguemeni Tiako MJ; Friedman A; Culhane J; South E; Meisel ZF
    Obstet Gynecol; 2021 Apr; 137(4):687-694. PubMed ID: 33706349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.
    Yedinak JL; Goedel WC; Paull K; Lebeau R; Krieger MS; Thompson C; Buchanan AL; Coderre T; Boss R; Rich JD; Marshall BDL
    PLoS Med; 2019 Nov; 16(11):e1002963. PubMed ID: 31743335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
    Spithoff S; Meaney C; Urbanoski K; Harrington K; Que B; Kahan M; Leece P; Shehadeh V; Sullivan F
    Can Fam Physician; 2019 Oct; 65(10):e443-e452. PubMed ID: 31604755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ambivalence and Stigma Beliefs About Medication Treatment Among Young Adults With Opioid Use Disorder: A Qualitative Exploration of Young Adults' Perspectives.
    Bagley SM; Schoenberger SF; dellaBitta V; Lunze K; Barron K; Hadland SE; Park TW
    J Adolesc Health; 2023 Jan; 72(1):105-110. PubMed ID: 36216678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.